natgillin/translations-raw huggingface dataset:
Non-nucleoside Reverse Transcriptase Inhibitors
Nenukleozidni inhibitori reverzne transkriptaze
Non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz, delavirdine, nevirapine) (used for treating HIV) (some doses of efavirenz can NOT be taken at the same time as VFEND)
nenukleozidne inhibitore reverzne transkriptaze (npr. efavirenz, delavirdin, nevirapin) (koriste se za liječenje HIV-a) (neke doze efavirenza NE smiju se uzimati u isto vrijeme kad i VFEND)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Inhibitori nenukleozidne reverzne transkriptaze (NNRTI)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nenukleozidni inhibitori reverzne transkriptaze (NNRTI)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nenukleozidni inhibitori reverzne transkriptaze (NNRTI-jevi)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nenukleozidni inhibitori reverzne transkriptaze (NNRTI; engl. non-nucleoside reverse transcriptase inhibitor)
Non-obese
nepretili
Non-prescribed overdoses had a median of 6 mg.
Predoziranje je u slučajevima nepropisane doze lijeka imala medijan od 6 mg.
Non-Procedural PLATO Major
Ne-proceduralna PLATO velika
Non-Procedural PLATO Major + Minor
Ne-proceduralna PLATO velika + manja
Non-radiographic axial spondyloarthritis
Aksijalni spondiloartritis bez radiografskih dokaza
Non-radiographic axial spondyloarthritis (nr-Axial SpA)
Aksijalni spondiloartritis bez radiološkog dokaza
Non-radiographic axial spondyloarthritits
Ne-radiografski aksijalni spondiloartritits
Non-responder
bolesnici koji nisu ostvarili odgovor
Non-responder Imputation (NRI) is used for patients who escaped therapy or had missing data.
Imputacija bolesnika bez odogovora koristi se za bolesnike koji su izbjegli terapiju ili za koje su nedostajali podaci.
Non-responder in Period A
Nisu odgovorili u Razdoblju A
Non-responder, n (%)
91,7 (12,1)
Non-responder, n (%)
Bez odgovora, n (%)
Non-responder, n (%)
Ispitanici bez odgovora, n (%)
Non-responder, n (%)
Nisu odgovorili, n (%)
Non-responders
Bolesnici bez odgovora
Non-responders (non-SVR12)
Bolesnici bez odgovora (bez SVR12)
non-responders or responders respectively), PSA response (declines in serum PSA levels of at least 50%), pain progression [assessed using the Present Pain Intensity (PPI) scale from the
Present Pain Intensity, PPI) iz McGill-Melzackovog upitnika te analgetske ljestvice (engl.
Non-responders to prior therapy with pegylated interferon alpha/ribavirin were less likely to achieve a week 12 response to retreatment than non-responders to non-pegylated interferon alpha/ribavirin (12.4% vs.
Vjerojatnost da će postići odgovor na ponovljeno liječenje u 12. tjednu bila je manja u bolesnika koji nisu uspješno odgovorili na prethodno liječenje pegiliranim interferonom alfa/ribavirinom nego u bolesnika koji nisu uspješno odgovorili na liječenje nepegiliranim interferonom alfa/ribavirinom (12,4 % u odnosu na 28,6 %).
Non-responders to prior therapy with pegylated interferon alpha/ribavirin were less likely to achieve a week 12 response to retreatment than non-responders to nonpegylated interferon alpha/ribavirin (12.4 % vs.
Vjerojatnost da će postići odgovor na ponovljeno liječenje u 12. tjednu bila je manja u bolesnika koji nisu odgovorili na prethodno liječenje pegiliranim interferonom alfa/ribavirinom nego u bolesnika koji nisu odgovorili na liječenje nepegiliranim interferonom alfa/ribavirinom (12,4% naspram 28,6%).
Non-respondersa N = 69
83,8 (67/80)
Non-response
Bez odgovora
Non-response
Izostanak odgovora
Non-response to therapy with Aranesp should prompt a search for causative factors.
Izostanak odgovora na terapiju Aranespom mora potaknuti potragu za uzročnim faktorima.
non-selective phosphodiesterase inhibitors like pentoxifylline, selective phosphodiesterase 3 (PDE3) inhibitors like cilostazol or anagrelide,
neselektivni inhibitori fosfodiesteraze, kao što je pentoksifilin, selektivni inhibitori fosfodiesteraze 3 (PDE 3), kao što su cilostazol ili anagrelid
non-selective phosphodiesterase inhibitors, such as pentoxifylline, selective phosphodiesterase (PDE 3) inhibitors, such as cilostazol or anagrelide,
neselektivne inhibitore fosfodiesteraze, kao što je pentoksifilin selektivne inhibitore fosfodiesteraze (PDE 3), kao što su cilostazol ili anagrelid
Non-serious cases of keratitis have been observed in 0.2 to 0.7% of clinical trial patients.
Slučajevi keratitisa, koji nisu ocijenjeni ozbiljnima, primijećeni su u 0,2 do 0,7% bolesnika u kliničkim ispitivanjima.
Non-serious infections with usual response to standard care and not requiring discontinuation of Cosentyx were reported in the remaining 3 cases.
U preostala 3 slučaja zabilježene infekcije nisu bile ozbiljne, odgovarale su na uobičajeno standardno liječenje i nisu zahtijevale prekid liječenja Cosentyxom.
Non-Small Cell Lung Cancer (NSCLC)
Rak pluća nemalih stanica
Non-Small Cell Lung Cancer (NSCLC):
Rak pluća nemalih stanica:
Non-small cell lung cancer (Tarceva administered as monotherapy):
Rak pluća nemalih stanica (primjena lijeka Tarceva kao monoterapije):
Non-species related breakpoints2
Granične vrijednosti nevezane za vrstu2
Non-specific skin rashes
nespecifični kožni osip
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q- wave myocardial infarction): clopidogrel treatment should be initiated with a single 300-mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda): liječenje klopidogrelom treba započeti s jednokratnom udarnom dozom od 300 mg, a zatim nastaviti sa 75 mg jedanput dnevno (uz acetilsalicilatnu kiselinu (ASK) 75 mg do 325 mg na dan).
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda), liječenje klopidogrelom treba započeti s jednokratnom udarnom dozom od 300 mg, a zatim nastaviti sa 75 mg jedanput dnevno (uz acetilsalicilatnu kiselinu (ASK) 75 mg do 325 mg dnevno).
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda): liječenje klopidogrelom treba započeti s jednokratnom udarnom dozom od 300 mg, a zatim nastaviti sa 75 mg jedanput dnevno (uz acetilsalicilatnu kiselinu (ASK) 75 mg do 325 mg dnevno).
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA)
Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda), uključujući bolesnike koji se podvrgavaju ugradnji stenta nakon perkutane koronarne intervencije, u kombinaciji s acetilsalicilatnom kiselinom (ASK).
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda), uključujući bolesnike koji se podvrgavaju ugradnji stenta nakon perkutane koronarne intervencije, u kombinaciji s acetilsalicilatnom kiselinom (ASK).
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
Akutnim koronarnim sindromom bez elevacije ST segmenta (nestabilna angina ili infarkt miokarda bez Q-valova), uključujući bolesnike podvrgnute postavljanju stenta nakon perkutane koronarne intervencije, u kombinaciji s acetilsalicilnom kiselinom (ASA).
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA)
Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda): liječenje klopidogrelom treba započeti s jednokratnom udarnom dozom od 300 mg, a zatim nastaviti sa 75 mg jedanput na dan (uz acetilsalicilatnu kiselinu (ASK) 75 mg do 325 mg na dan).
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Akutni koronarni sindrom bez elevacije ST segmenta (nestabilna angina ili infarkt miokarda bez Q- valova): liječenje klopidogrelom valja započeti jednom udarnom dozom od 300 mg te nastaviti primjenom 75 mg jednom dnevno (uz acetilsalicilnu kiselinu (ASA) u dozi od 75 mg – 325 mg jednom dnevno).
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda): liječenje klopidogrelom treba započeti s jednokratnom udarnom dozom od 300 mg, a zatim nastaviti sa 75 mg jedanput dnevno (uz acetilsalicilatnu kiselinu (ASK) 75 mg do 325 mg dnevno).
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda): liječenje klopidogrelom treba započeti s jednokratnom udarnom dozom od 300 mg, a zatim nastaviti sa 75 mg jedanput na dan (uz acetilsalicilnu kiselinu (ASK) 75 mg do 325 mg na dan).
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300-mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda): liječenje klopidogrelom treba započeti s jednokratnom udarnom dozom od 300 mg, a zatim nastaviti sa 75 mg jedanput dnevno (uz acetilsalicilatnu kiselinu (ASK) 75 mg do 325 mg dnevno).
Non-Steroidal Anti-
Nesteroidni protuupalni lijekovi (NSAR)
Non-steroidal anti- inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid (>3 g/day), and non-  selective NSAIDs
Nesteroidni protuupalni lijekovi (NSAILi), uključujući selektivne inhibitore ciklooksigenaze-2 (COX-2 inhibitore), acetilsalicilatnu kiselinu (>3 g/dan) i neselektivne NSAIL-e
Non-steroidal anti- inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid (>3 g/day), and non- selective NSAIDs
Nesteroidni protuupalni lijekovi (NSAILi), uključujući selektivne inhibitore ciklooksigenaze-2 (COX-2 inhibitore), acetilsalicilatnu kiselinu (>3 g/dan) i neselektivne NSAIL-e
non-steroidal anti-inflammatory drugs
nesteroidne protuupalne lijekove
Non-steroidal anti-inflammatory drugs (e.g., ibuprofen, diclofenac) (used for treating pain and inflammation)
nesteroidne protuupalne lijekove (npr. ibuprofen, diklofenak) (koriste se za liječenje boli i upale)
Non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid > 3 g/day), and non-selective NSAIDs
Nesteroidni protuupalni lijekovi (NSAIL), uključujući selektivne COX-2 inhibitore, acetilsalicilatnu kiselinu (> 3 g na dan) i neselektivne NSAIL
Non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid > 3 g/day), and non-selective NSAIDs
Nesteroidni protuupalni lijekovi (NSAIL), uključujući selektivne COX-2 inhibitore, acetilsalicilnu kiselinu ( > 3 g na dan) i neselektivne NSAIL
Non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid > 3 g/day), and non-selective NSAIDs
Nesteroidni protuupalni lijekovi (NSAIL), uključujući selektivne COX-2 inhibitore, acetilsalicilnu kiselinu (> 3 g na dan) i neselektivne NSAIL
Non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid and non-selective NSAIDs: As with other agents acting on the renin-angiotensin system, NSAIDs may reduce the anti-hypertensive effect of aliskiren.
Nesteroidni protuupalni lijekovi (NSAIL-i), uključujući selektivne inhibitore ciklooksigenaze-2 (COX-2 inhibitore), acetilsalicilna kiselina i neselektivni NSAIL-i: kao i s drugim lijekovima koji djeluju na renin-angiotenzin sustav, i NSAIL-i mogu smanjiti antihipertenzivni učinak aliskirena.
Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac or celecoxib (medicines to relieve pain and inflammation)
nesteroidne protuupalne lijekove, kao što su ibuprofen, diklofenak ili celekoksib (lijekovi za ublažavanje bolova i upale)
Non-steroidal anti-inflammatory drugs (NSAIDs): Concomitant administration with chronic NSAIDs has not been studied.
Nesteroidni protuupalni lijekovi (NSAIL): Nije ispitivana istodobna primjena kod kroničnog liječenja NSAIL-ima.
non-steroidal anti-inflammatory drugs,
nesteroidne protuupalne lijekove,
non-steroidal anti-inflammatory medicinal products,
nesteroidni protuupalni lijekovi,
Non-steroidal anti-inflammatory medicines (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid (>3 g/day), and non-selective NSAIDs
Nesteroidni protuupalni lijekovi (NSAILi), uključujući selektivne COX-2 inhibitore, acetilsalicilatnu kiselinu (>3 g/dan) i neselektivne NSAIL-e
Non-susceptible organisms
Organizmi koji nisu osjetljivi na lijek
Non-sustained convulsions were observed in some monkeys receiving efavirenz for � 1 year, at doses yielding plasma AUC values 4- to 13-fold greater than those in humans given the recommended dose (see sections 4.4 and 4.8).
Nepostojane konvulzije zapažene su u nekih majmuna koji su efavirenz primali ≥1 godine u dozama kojima je postignut 4 do 13 puta viši AUC u plazmi od onog u ljudi koji su primali preporučenu dozu lijeka (vidjeti dijelove 4.4 i 4.8).
Non-transfusion-dependent thalassaemia syndromes are blood disorders similar to beta thalassaemia major but which do not require blood transfusions.
Sindromi talasemije neovisni o transfuziji poremećaji su krvi slični beta-talasemiji major, ali nisu povezani s transfuzijom krvi.
non-valvular atrial fibrillation patients taking apixaban for the prevention of stroke and systemic embolism, the results demonstrate a less than 1.7-fold fluctuation in peak-to-trough levels.
U bolesnika s nevalvularnom atrijskom fibrilacijom koji uzimaju apiksaban za prevenciju moždanog udara i sistemske embolije, rezultati pokazuju da je fluktuacija između najviše i najniže razine manja od 1,7 puta.
Non-vertebral fracture (1)
Nevertebralni prijelom (1)
Non-vertebral fracture2
Nevertebralna fraktura2
Non-YMDD1
Bez-YMDD1
Nonacog alfa (recombinant coagulation factor IX) Intravenous use
nonakog alfa (rekombinantni koagulacijski faktor IX) Primjena u venu
Nonacog alfa is not extracted from human blood but produced by a method known as ‘recombinant DNA technology’: it is made by cells that have received a gene (DNA), which makes them able to produce human coagulation factor IX.
Nonakog alfa se ne ekstrahira iz ljudske krvi, nego se proizvodi metodom poznatom kao „tehnologija rekombinantne DNK”: ovu tvar proizvode stanice koje su primile gen (DNK) koji im omogućuje stvaranje ljudskog koagulacijskog faktora IX.
Nonacog gamma (recombinant human coagulation factor IX)
nonakog gama (rekombinantni ljudski faktor zgrušavanja IX)
Nonafact 100 IU/ml powder and solvent for solution for injection Human coagulation factor IX
Nonafact 100 IU/ml prašak i otapalo za otopinu za injekciju ljudski faktor zgrušavanja IX
Nonafact 100 IU/ml powder and solvent for solution for injection.
Nonafact 100 IU/ml prašak i otapalo za otopinu za injekciju.
Nonafact 100 IU/ml powder for solution for injection Human coagulation factor IX
Nonafact 100 IU/ml prašak za otopinu za injekciju ljudski faktor zgrušavanja IX
Nonafact can be administered to prevent and treat bleeding in patients suffering from haemophilia B (a congenital lack of active factor IX).
Nonafact se može primijeniti za sprečavanje i liječenje krvarenja u pacijenata koji boluju od hemofilije B (prirođeni nedostatak aktivnog faktora IX).
Nonafact consists of a carton containing:
Nonafact se sastoji od pakovanja koje sadrži:
Nonafact contains 100 IU/ml (500 IU/5ml or 1000 IU/10ml) human coagulation factor IX when reconstituted with 5 ml or 10 ml, respectively, of water for injections.
Nonafact sadrži 100 IU/ml (500 IU/5ml ili 1000 IU/10ml) ljudskog faktora koagulacije IX nakon pripreme s 5 ml ili 10 ml vode za injekcije.
Nonafact contains trace amounts (< 0.1 ng mouse IgG/IU of factor IX) of the murine monoclonal antibody used in its purification.
Nonafact sadrži u tragovima (< 0,1 ng mišjeg IgG/IU faktora IX) murino monoklonalno protutijelo koje se koristi za pročišćavanje.
Nonafact has no influence on the ability to drive and use machines.
Nonafact ne utječe na sposobnost upravljanja vozilima i rada na strojevima.
Nonafact has no known effects on the ability to drive and to use machines.
Nonafact ne utječe na sposobnost upravljanja vozilima i rada na strojevima.
Nonafact is given to you by your doctor or nurse.
Nonafact će Vam dati liječnik ili sestra.
Nonafact is presented as a powder and a solvent for solution for injection (vial of 5 ml or 10 ml)
Nonafact je prašak i otapalo za otopinu za injekciju (bočica od 5 ml ili 10 ml)
Nonafact may be self administered if it is an approved practice in your country and when you have been trained sufficiently.
Nonafact si možete davati i sami ako je to odobreno u Vašoj državi i ako ste dovoljno uvježbani.
Nonafact should be injected into a vein (intravenous administration).
Nonafact treba ubrizgati u venu (intravenska primjena).
Nonafact should never be mixed with other medicinal products.
Nonafact se ne smije miješati s drugim lijekovima.
Noncirrhosis
Bez ciroze
Nonclinical data did not reveal special hazards for humans based on conventional studies of reproductive toxicity.
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja reproduktivne toksičnosti.
Nonclinical data do not show any effects of brinzolamide or brimonidine on fertility.
Neklinički podaci ne ukazuju na utjecaj brinzolamida ili brimonidina na plodnost.
Nonclinical data performed with tenecteplase have shown bleeding with secondary mortality of dams due to the known pharmacological activity of the active substance and in a few cases abortion and resorption of the foetus occurred (effects only have been observed with repeated dose administration).
Podaci iz nekliničkih ispitivanja provedenih s tenekteplazom pokazali su krvarenje uz sekundarnu smrtnost ženki zbog poznate farmakološke aktivnosti djelatne tvari, kao i nekoliko slučajeva s pojavom prekida trudnoće i resorpcije fetusa (ovi učinci su primijećeni isključivo uz primjenu ponovljenih doza).
Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza i genotoksičnosti,.
Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential and toxicity to reproduction and development.
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti, kancerogenosti, reproduktivne i razvojne toksičnosti.
Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to fertility, reproduction and development.
Neklinički podaci koji se temelje na konvencionalnim istraživanjima sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti kancerogenog potencijala i reprodukcijske toksičnosti, nisu pokazala opasnost za čovjeka.
Nonclinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenic potential.
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti, kancerogenog potencijala, reproduktivne i razvojne toksičnosti.
Nonclinical in vitro experiments in nonsense mutation cellular assays and fish larvae cultured in an ataluren solution have shown that ataluren enabled ribosomal readthroughwith a bell-shaped (inverted- U shaped) concentration-response relationship.
Neklinički in vitro pokusi na stanicama s besmislenom mutacijom i ribljim ličinkama kultiviranim u otopini atalurena pokazali su ribosomalnu translaciju omogućenu atalurenom sa zvonolikim (obrnuti oblik slova U) odnosom koncentracije i odgovora.
Nonclinical studies in rats have shown that olaparib causes adverse effects on embryofoetal survival and induces major foetal malformations at exposures below those expected at the recommended human dose of 400 mg twice daily.
Neklinička istraživanja na štakorima pokazala su da olaparib štetno utječe na preživljenje embrija/fetusa te inducira značajne malformacije ploda pri izloženostima manjima od onih očekivanih nakon primjene preporučene doze za ljude od 400 mg dvaput na dan.
Nondepolarizing skeletal muscle relaxants (e.g. tubocurarine)
Nedepolarizirajući relaksansi koštanih mišića (primjerice tubokurarin)
Nondepolarizing skeletal muscle relaxants (e.g. tubocurarine)
Nedepolarizirajući relaksansi skeletnog mišića (npr. tubokurarin)
Nondepolarizing skeletal muscle relaxants (e.g. tubocurarine)
Nedepolarizirajući relaksansi skeletnog mišićja (npr. tubokurarin)
None
Bez mutacije
none
doziranju
None
Nema ih.
None
nikakva
none
odgovarajuće
None a AUC 20% ↑ a Cmax 20% ↑
Nema a AUC 20% ↑ a Cmax 20% ↑
None Grade 1-2 Grade 3-4*
nema stupanj 1-2 stupanj 3-4
None had any infusion-related or peri-infusional hypersensitivity or anaphylactic reactions.
Niti jedan nije imao preosjetljivost povezanu s infuzijom ili periinfuzijsku preosjetljivost ili anafilaktičku reakciju.
None known
Nisu poznate
None known.
Nema poznatih
None known.
Nisu poznate
None known.
Nisu primjenjivo.
None of cases was of severe intensity and led to treatment discontinuation.
Niti jedan od slučajeva nije bio toliko snažnog intenziteta da bi doveo do prekidaliječenja.
None of the 12 patients experienced withdrawal symptoms.
Nijedan od 12 bolesnika nije imao simptome ustezanja.
None of the 12 patients experienced withdrawal symptoms.
Takrolimus može biti povezan s torsades de pointes.
None of the 99 MabThera-treated patients were HACA positive at screening.
Niti jedan od 99 bolesnika liječenih lijekom MabThera nije bio pozitivan na HACA-u pri probiru.